If you're all about going back into the robotic land of big pharma, then more power to you.... But I think most would regret a decision like that over time.
As far as Rio goes, who is going to use it? Sure, it'll be used in CTEPH patients, but once that business gets saturated up, then what? There is absolutely zero benefit to using Rio over a PDE5 (and you can't use both together), and they are going to price it like an ERA.... and it is TID..... and it has to be titrated.... and there is going to be a real risk of systemic hypotension.... Bayer is going to price Rio out of the market....
Be careful about the decision to go over to Bayer. I highly doubt they'll come anywhere close to the expectations they have for their drug. IMO.